Valacyclovir Resistance in HSV – Clinical Recognition and Management

Clinical Indicators

Persistent or progressive HSV lesions that have not begun to resolve after 7–10 days of appropriate valacyclovir therapy are the primary sign of resistance, especially in immunocompromised hosts. CDC guidance. 1
Lesions that persist or worsen despite adequate valacyclovir dosing should immediately raise suspicion for drug resistance. Evidence drawn from multiple CDC reports. 2, 3, 4

Severely immunocompromised individuals, notably patients with HIV/AIDS, are the populations in which valacyclovir resistance occurs almost exclusively. CDC recommendations. 2, 1
In these hosts, resistance often presents as severe, painful, and atypical HSV lesions. CDC observations. 2, 4

When resistance is suspected, obtain a viral culture from the lesion with susceptibility testing before changing therapy; this step directs appropriate alternative treatment. CDC protocol. 1

All acyclovir‑resistant HSV strains are also resistant to valacyclovir, because valacyclovir is a pro‑drug of acyclovir. CDC data. 2, 3, 4
The majority of acyclovir‑resistant isolates are cross‑resistant to famciclovir as well. CDC findings. 2, 3

Intravenous foscarnet 40 mg/kg every 8 hours until clinical resolution is the treatment of choice for confirmed resistance. CDC recommendation. 2, 1, 3
For external mucocutaneous disease, topical cidofovir 1 % gel applied daily for 5 days may be used as adjunctive therapy. CDC guidance. 2, 4
Topical trifluridine or imiquimod are alternative options, requiring prolonged application (approximately 21–28 days). CDC suggestion. 1

Consult an infectious‑disease specialist when managing confirmed valacyclovir‑resistant HSV to optimize therapy. CDC recommendation. 2, 3, 4

Do not switch to famciclovir for suspected acyclovir/valacyclovir resistance because of common cross‑resistance. CDC warning. 2
Do not delay viral culture with susceptibility testing once resistance is suspected; timely testing guides definitive therapy. CDC advice. 1

The Centers for Disease Control and Prevention recommends that HIV-infected patients may experience more frequent and severe herpes infections requiring higher doses of valacyclovir 5
In immunocompromised patients, high-dose valacyclovir (8g/day) has been associated with TTP/HUS 5
At standard doses for genital herpes, valacyclovir is generally safe in immunocompromised patients 5
For mild adverse reactions (headache, nausea), symptomatic treatment is usually sufficient, as suggested by the International Society for Antiviral Research 6
All acyclovir-resistant strains are also resistant to valacyclovir, and alternative therapy with foscarnet (40 mg/kg IV every 8 hours) may be required, according to the Centers for Disease Control and Prevention 5

The Centers for Disease Control and Prevention recommends that HIV-infected patients may require higher doses of valacyclovir but face increased risk of TTP/HUS at doses of 8 grams/day, particularly those with advanced HIV-1 disease, allogeneic bone marrow transplant recipients, and renal transplant recipients 7
At standard therapeutic doses for genital herpes, the risk of TTP/HUS appears minimal in immunocompromised patients, according to the MMWR Recommendations and Reports 7